Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

OBJECTIVE: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. METHODS: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-bl...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Neurol
Huvudupphovsmän: Coelho, Teresa, Yarlas, Aaron, Waddington-Cruz, Marcia, White, Michelle K., Sikora Kessler, Asia, Lovley, Andrew, Pollock, Michael, Guthrie, Spencer, Ackermann, Elizabeth J., Hughes, Steven G., Karam, Chafic, Khella, Sami, Gertz, Morie, Merlini, Giampaolo, Obici, Laura, Schmidt, Hartmut H., Polydefkis, Michael, Dyck, P. James B., Brannagan III, Thomas H., Conceição, Isabel, Benson, Merrill D., Berk, John L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Berlin Heidelberg 2019
Ämnen:
Original Communication
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109169/
https://ncbi.nlm.nih.gov/pubmed/31853709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-019-09671-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk